Erastin: Ferroptosis Inducer Targeting RAS/BRAF-Mutant Tumors

Executive Summary: Erastin (CAS 571203-78-6) is a small molecule that induces ferroptosis, a regulated, iron-dependent, non-apoptotic cell death pathway, by inhibiting the cystine/glutamate antiporter system Xc⁻ and modulating the voltage-dependent anion channel (VDAC) (Liu et al., 2022). It selectively kills tumor cells with oncogenic KRAS, HRAS, or BRAF mutations and is widely used to dissect oxidative stress and redox homeostasis in cancer models (APExBIO B1524). Erastin is insoluble in water but dissolves in DMSO at concentrations ≥10.92 mg/mL with gentle warming. Typical experimental protocols use 10 μM for 24 hours in engineered tumor cell lines. The compound is a reference standard for ferroptosis research and is critical for studies exploring novel cancer therapeutics targeting iron metabolism and oxidative cell death (Erastin: Ferroptosis Inducer Targeting RAS/BRAF-Mutant Tumors).

Biological Rationale

Ferroptosis is a distinct form of regulated cell death dependent on iron and characterized by the accumulation of lipid peroxides. Unlike apoptosis or necroptosis, ferroptosis does not involve caspase activation or classic morphological changes associated with apoptosis (Liu et al., 2022). Tumor cells harboring activating mutations in the RAS family (KRAS, HRAS) or BRAF genes rely on redox homeostasis and cystine import for survival. Erastin exploits this metabolic vulnerability by inhibiting cystine uptake, thereby triggering oxidative damage and cell death in these cancer cells (Erastin: Precision Ferroptosis Inducer for Cancer Biology). This mechanism is of particular relevance for cancers that are refractory to apoptosis-inducing therapies.

Mechanism of Action of Erastin

Erastin acts through two principal molecular targets:

• Inhibition of System Xc⁻ (SLC7A11/SLC3A2): Erastin competitively inhibits the cystine/glutamate antiporter, decreasing cystine uptake and depleting intracellular glutathione (GSH) (APExBIO B1524).
• Modulation of VDAC (Voltage-Dependent Anion Channel): Erastin binds and alters VDAC function, facilitating increased production of reactive oxygen species (ROS) within mitochondria, compounding oxidative stress.

This dual action disrupts cellular redox balance, resulting in lipid peroxidation and iron-dependent, caspase-independent cell death. Notably, Erastin does not induce apoptosis or necroptosis, establishing it as a precise ferroptosis inducer (Erastin: Unraveling Ferroptosis and Caspase-Independent Cell Death). This mechanistic specificity makes Erastin a valuable probe for delineating the boundaries of oxidative cell death pathways in cancer biology research.

Evidence & Benchmarks

• Erastin induces ferroptosis in RAS- and BRAF-mutant hepatoma, colon, and ovarian cancer cell lines, but not in melanoma cells under identical in vitro conditions (Liu et al., 2022, DOI).
• Systemic administration of Erastin (10 μM, 24 h) reduces tumor growth in human tumor xenograft models (Liu et al., 2022, DOI).
• When combined with oncolytic vaccinia virus, Erastin enhances dendritic cell activation and tumor-infiltrating CD8+ T cell responses (Liu et al., 2022, DOI).
• Erastin shows no significant direct effect on systemic or local antitumor immunity when used alone, underscoring its cytotoxic, not immunomodulatory, primary action (Liu et al., 2022, DOI).
• Erastin is insoluble in water and ethanol but is soluble in DMSO at ≥10.92 mg/mL with gentle warming; compound stability is optimal at -20°C, and solutions should be freshly prepared for each experiment (APExBIO B1524).

Applications, Limits & Misconceptions

Erastin is a reference compound for:

• Ferroptosis research in engineered tumor models, especially those with RAS/RAF pathway mutations.
• Oxidative stress and redox homeostasis assays in cancer biology.
• Dissection of iron-dependent, non-apoptotic cell death mechanisms.
• Preclinical evaluation of combinatorial cancer therapies involving ferroptosis induction and immunotherapy (Erastin: Optimizing Ferroptosis Induction in Cancer Biology)—this article expands on protocol optimization for experimental success.

Contrasting prior work, this article updates the comprehensive benchmarks from Erastin: Ferroptosis Inducer Targeting RAS/BRAF-Mutant Tumors by integrating the latest immuno-oncology findings.

Common Pitfalls or Misconceptions

• Erastin does not induce apoptosis or necroptosis; effects are iron- and ROS-dependent.
• Ineffective at killing tumor cells lacking RAS or BRAF mutations under standard dosing.
• Stability in solution is poor; do not use stored solutions for quantitative assays.
• Insoluble in water and ethanol; DMSO is required for experimental stock solutions.
• No direct immune cell activation when used as a single agent, limiting immunotherapy applications unless combined with additional modalities.

Workflow Integration & Parameters

For optimal experimental outcomes:

• Use freshly prepared Erastin stock solutions in DMSO at ≥10.92 mg/mL.
• Standard treatment: Tumor cells (e.g., HT-1080) exposed to 10 μM Erastin for 24 hours at 37°C, 5% CO₂.
• Monitor cell viability via lipid peroxidation assays, GSH quantification, and live/dead staining.
• Store Erastin powder at -20°C, protected from moisture and light; avoid freeze-thaw cycles.
• Combine with oncolytic viruses or immune checkpoint modulators for advanced mechanistic studies.

The Erastin reagent from APExBIO (B1524) is supplied as a solid suitable for high-throughput cancer screening and mechanistic cell death assays.

For deeper protocol optimization and troubleshooting, readers may consult Erastin: Precision Ferroptosis Inducer for Cancer Biology, which provides workflow guidance. This article extends that guide by clarifying Erastin's role in combination therapy studies.

Conclusion & Outlook

Erastin stands as a gold-standard ferroptosis inducer for selective targeting of RAS- and BRAF-mutant tumor cells. Its well-characterized mechanism—cystine/glutamate antiporter inhibition and VDAC modulation—enables precise modeling of oxidative, iron-dependent cell death. While Erastin alone is not immunomodulatory, its integration with oncolytic virotherapy or immune checkpoint blockade holds significant promise for next-generation cancer therapies (Liu et al., 2022). APExBIO's Erastin (B1524) remains a cornerstone reagent for cancer biology, redox research, and translational studies pursuing ferroptosis-based interventions.